Skip Navigation


Annals of Oncology Advance Access originally published online on October 19, 2005
Annals of Oncology 2006 17(1):135-140; doi:10.1093/annonc/mdj025
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/1/135    most recent
mdj025v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tanimoto, K.
Right arrow Articles by Tobinai, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanimoto, K.
Right arrow Articles by Tobinai, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma

K. Tanimoto1, A. Kaneko2, S. Suzuki2, N. Sekiguchi1, D. Maruyama1, S. W. Kim1, T. Watanabe1, Y. Kobayashi1, Y. Kagami3, A. Maeshima4, Y. Matsuno4 and K. Tobinai1,*

1 Hematology and Stem Cell Transplantation Division, 2 Ophthalmology Division, 3 Radiation Oncology Division and 4 Pathology Division, National Cancer Center Hospital and Research Institute, Tokyo, Japan

* Correspondence to: Dr K. Tobinai, Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan 104-0045. Tel: +81-3-3542-2511; Fax: +81-3-3542-3815; E-mail: ktobinai{at}ncc.go.jp

Background: The majority of lymphomas in the ocular adnexa are low-grade B-cell lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma). Although radiotherapy is the most frequently applied management, cataract and dry eye are problematic complications.

Patients and methods: Between 1973 and 2003, the clinical features of 36 patients with ocular adnexal MALT lymphoma with no symptoms who were managed with no initial therapy after biopsy or surgical resection were retrospectively analyzed.

Results: The median patient age was 63 years (range 22–84) and all patients had stage I disease, consisting of 31 unilateral cases and five bilateral cases. With a median follow-up of 7.1 years, 25 (69%) did not require treatment. The median time until the initiation of treatment in the remaining 11 patients (31%) was 4.8 years. Six patients (17%) died, and among them only two (6%) died due to progressive lymphoma. Seventeen patients (47%) progressed, but histologic transformation was recognized in only one (3%). The estimated overall survival rates of the 36 patients after 5, 10 and 15 years were 94%, 94% and 71%, respectively.

Conclusions: In selected patients with ocular adnexal MALT lymphoma, no initial therapy might be an acceptable approach, because 70% of patients remained untreated at a median of 8.6 years, and their survival was comparable to that of reports on immediate therapy.

Key words: MALT lymphoma, ocular adnexa, no initial therapy, prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al.
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Ann. Onc., May 1, 2008; 19(5): 835 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al.
Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 242 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
E. Hatef, D. Roberts, P. McLaughlin, B. Pro, and B. Esmaeli
Prevalence and Nature of Systemic Involvement and Stage at Initial Examination in Patients With Orbital and Ocular Adnexal Lymphoma
Arch Ophthalmol, December 1, 2007; 125(12): 1663 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Tanimoto, A. Kaneko, S. Suzuki, N. Sekiguchi, T. Watanabe, Y. Kobayashi, Y. Kagami, A. M. Maeshima, Y. Matsuno, and K. Tobinai
Primary Ocular Adnexal MALT Lymphoma: A Long-term Follow-up Study of 114 Patients
Jpn. J. Clin. Oncol., June 11, 2007; (2007) hym031v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Tsai, S Li, A. Ng, B Silver, M. Stevenson, and P. Mauch
Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma
Ann. Onc., April 1, 2007; 18(4): 672 - 678.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic
Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options
Blood, September 1, 2006; 108(5): 1451 - 1460.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Arcaini, S. Burcheri, A. Rossi, F. Passamonti, M. Paulli, E. Boveri, E. Brusamolino, E. Orlandi, A. Molteni, A. Pulsoni, et al.
Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination.
Oncologist, March 1, 2006; 11(3): 285 - 291.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.